Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. Academic Article uri icon

Overview

abstract

  • The cancer-testis antigen, NY-ESO-1, has been engineered into a bacterial expression plasmid which incorporates a His6-tag. The plasmid was transfected into E. coli strain BL21 and Master and Working cell banks generated from this expression system. Three 15-litre fermentations were performed under cGMP (code of Good Manufacturing Practice) conditions and the crude NY-ESO-1 tagged protein isolated as solubilised inclusion bodies. A three-step cGMP chromatography process (immobilised metal affinity, anion exchange, and hydrophobic interaction) was utilised to purify the protein. The purified NY-ESO-1 is being used in early stage human cancer vaccine trials in Australia and the U.S.A.

publication date

  • January 1, 2005

Research

keywords

  • Antigens, Neoplasm
  • Cancer Vaccines
  • Membrane Proteins
  • Protein Engineering

Identity

Scopus Document Identifier

  • 20244384857

PubMed ID

  • 15881594

Additional Document Info

volume

  • 35

issue

  • 2